Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

12/30/2004 9:45:04 AM ET

Financing in Place for National U.S. Launch of O24 Pain Relief Product

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

December 30, 2004

Financing in Place for National U.S. Launch of O24 Pain Relief Product

Toronto, Canada – Swiss Medica is pleased to announce it has signed definitive agreements for debt financing,

resulting in gross proceeds of US$1.5 million to fund the inventory and marketing requirements for the National U.

S. launch of the Company’s flagship O24™ pain relief product.

“This debt financing allows us to execute the launch phase of our ambitious marketing plan in the United States

by using the same cost-efficient media strategy that has brought the O24 product a spectacular and devoted

following in Canada,” said Chief Executive Officer Raghu Kilambi. “Funds were raised from a group of

institutional and high net worth investors with minimal equity dilution.”

Full details of the financing will be incorporated in the Company’s 8-K filing with the U.S. Securities and

Exchange Commission.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Swiss Medica’s flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The

O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits

by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout

Canada in leading pharmacies and natural food stores. It is currently available in Happy Harry’s Discount

Drugstores in the United States, or by visiting

, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica

1 866 485 4243